US 12,390,518 B2
Immunogenic composition
Craig Thompson, Oxfordshire (GB); and Sunetra Gupta, Oxfordshire (GB)
Assigned to OXFORD UNIVERSITY INNOVATION LIMITED, Oxford (GB)
Filed by Oxford University Innovation Limited, Oxford (GB)
Filed on Aug. 27, 2021, as Appl. No. 17/458,712.
Application 17/458,712 is a continuation of application No. 16/326,749, granted, now 11,123,422, previously published as PCT/GB2017/052510, filed on Aug. 25, 2017.
Claims priority of application No. 1614485 (GB), filed on Aug. 25, 2016.
Prior Publication US 2022/0054625 A1, Feb. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/145 (2006.01); A61K 39/285 (2006.01); A61K 39/39 (2006.01); A61P 31/16 (2006.01); C07K 16/08 (2006.01); C07K 16/10 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/145 (2013.01) [A61K 39/285 (2013.01); A61K 39/39 (2013.01); A61P 31/16 (2018.01); C07K 16/08 (2013.01); C07K 16/1018 (2013.01); A61K 2039/5258 (2013.01)] 21 Claims
 
1. An immunogenic composition comprising two or more polypeptides, wherein each polypeptide independently comprises a first region of contiguous amino acids, wherein:
(a) the amino acid sequence of the first region has at least 80% sequence identity to an influenza A subtype H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, H17 or H18 haemagglutinin head domain; and
(b) the first region has amino acid substitutions at positions which correspond to the following positions in SEQ ID NO: 9:
position 83 is E
position 85 is a negatively charged amino acid
position 146 is T, N, I or A
position 147 is a positively charged amino acid, I or is absent
position 148 is G
position 149 is V
position 151 is A
position 154 is S or P
position 155 is H
position 156 is a positively charged amino acid or A or G or N or E
position 157 is a positively charged amino acid or A or G
position 158 is a positively charged amino acid or A or S or N or C or E
position 159 is K or A or S or N or C, and
position 163 is a positively charged amino acid,
wherein the amino acid sequences of the two or more polypeptides are different, and wherein the composition is capable of inducing antibodies in a subject against an influenza A virus, optionally together with one or more pharmaceutically-acceptable carriers, adjuvants, excipients or diluents.